Loading data for IRD — first visit, this takes a few seconds.

Alerta

Opus Genetics Inc. (IRD)

NasdaqCM: IRD · Precio en tiempo real · USD

3.85

+0.16 (4.34%)

Al cierre: Aug 19, 2026, 10:40 AM

4.34% (1D)

Precio de compra	2.63
Capitalización de mercado	335.7M
Ingresos (TTM)	9.86M
Beneficio neto (TTM)	-107.61M
Beta	0.58
EPS (TTM)	-1.29
Ratio PER (TTM)	n/a
Adelante PE	-5.69
P/B (TTM)	-25.70
P/S (TTM)	34.06
Earnings Date	Nov 11, 2026

Precio de venta	4.62
Volumen	188,044
Volumen medio (20D)	938,769
Abierto	3.76
Anterior Cerrar	3.69
Rango del día	3.76 - 3.91
Rango de 52 semanas	1.11 - 5.81
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de IRD

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The compa...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Nov 10, 2005

Empleados 27

Bolsa de Valores NasdaqCM

Símbolo bursátil IRD

Sitio web https://opusgtx.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Opus Genetics fueron 14.2M, un aumento de 29.15% en comparación con 10.99M del año anterior. Las ganancias fueron -49.59M, una disminución de -13.8%.

Estados financieros

Sorpresa de resultados

Opus Genetics ha publicado sus resultados trimestrales en Aug 6, 2026:

Ingresos de $755K falla las estimaciones por $0, con -73.80% Disminución interanual.

EPS de -0.08 supera las estimaciones en 0.08, con 33.33% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Opus Genetics Inc. publique sus resultados el Nov 11, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 semana hace · Zacks

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +6.67% and -75.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1 mes hace · Insider Monkey

RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup

Opus Genetics, Inc. (NASDAQ:IRD), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. A bullish new analyst call and a broadening gene therapy pipel...

2 meses hace · Insider Monkey

Guggenheim Initiates Coverage Of Opus Genetics (IRD) With “Buy” Rating And $16 Price Target

While Opus Genetics, Inc. (NASDAQ:IRD) has gained 100.50% year-to-date, analysts continue to see 148.10% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy. Fresh cover...

2 meses hace · MarketBeat

Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst

Opus Genetics (NASDAQ:IRD) is advancing a portfolio of gene therapies for inherited retinal diseases, with two programs already in the clinic and three more expected to enter clinical testing within t...

3 meses hace · Zacks

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -374.68% and -23.18%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Página 1 de 2

Opus Genetics Inc. (IRD)